Menu

Ozempic, Wegovy & Mounjaro: US FDA mandates safety warning for eye condition
📰

Ozempic, Wegovy & Mounjaro: US FDA mandates safety warning for eye condition

The Indian Express·6 days ago
#zTr3qpxk
Reading 0:00
15s threshold

The US Food and Drug Administration (FDA) has announced a significant safety labelling change for popular diabetes and weight-loss medications, including Ozempic, Wegovy, Mounjaro and Zepbound. The move follows concerns about a possible increased risk of a rare eye condition called Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), which can cause sudden, painless and sometimes permanent vision loss.

In its safety communication dated November 9, 2026, the FDA directed manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to include information about this potential risk in the Warnings and Precautions section of their product labels.

NAION is sometimes described as an “eye stroke.” It occurs when blood supply to the optic nerve, which carries visual information from the eye to the brain, is reduced. The resulting damage can affect vision in one eye, often suddenly and without pain. Some patients notice the problem upon waking up in the morning.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.